Collectively, our study provides direct proof for a critical role of the CRTC-CREB activation in maintaining the malignant phenotypes of LKB1-inactive lung cancers and reveals direct inhibition of the CRTC-CREB transcriptional complex via targeting the CRTC-CREB interface as a novel, promising therapeutic approach. This evidence concerns the gene STK11 and lung carcinoma.